Activian Clinical Research

The trials here

What the 11 trials at this site are about, from their registry records.

Conditions

• Obesity10 trials
• Type 2 diabetes6 trials
• Osteoarthritis2 trials
• COPD1 trial
• Type 1 diabetes1 trial

Phase

• Phase 38 trials
• Phase 22 trials

Status

• Active, not recruiting5 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company8 trials
• Pfizer2 trials
• Sanofi1 trial

Running trials

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

  Contact: Martin Basaldua (principal investigator)

• Recruiting

  A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

  NCT07919678· Phase 3· Pfizer· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Martin Basaldua (principal investigator)

• Recruiting

  The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

  NCT07612878· Sanofi· Source

  Contact: Katie Rice

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Pfizer· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

  Contact: Martin Basaldua (principal investigator)

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  NCT07153471· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT06972472· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

  NCT06972459· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

  NCT06993792· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity4 recruiting
• Type 2 diabetes2 recruiting
• COPD1 recruiting
• Osteoarthritis1 recruiting

Closed trials

• Withdrawn

  A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

  NCT06901349· Phase 2· Eli Lilly and Company· Source